The retinoid receptors (RARs and RXRs) are mediators of the multiple effects of retinoic acid. Of these, the retinoic acid receptor ␤2 (RAR␤2) has frequently been shown to be the principal mediator of the growth and tumor suppressive effects of retinoic acid; this gene is inactivated in many epithelial tumors and their derived cell lines. We have searched for genes that are regulated by this isoform and are potentially involved in tumor suppression. Using the Atlas human cDNA array I, we identified 27 genes (not counting RAR␤ itself) that are regulated, directly or indirectly, by RAR␤2 when it is transfected into Calu-1, a lung tumor-derived line that does not normally express RAR␤. Several of the affected genes code for proteins whose functions would augment the process of apoptosis and/or the host's immune response. The latter group included ICAM-1 and MHC class I heavy chain, whose protein products play particularly important roles in the mounting of an effective antitumor response. We then confirmed by flow cytometry that the observed increases in message levels were reflected in increased cell surface protein levels for ICAM-1 and MHC class I in RAR␤2 transfectants of two RAR␤-deficient lines, Calu-1 and the epidermoid lung cancer-derived line SK-MES. Finally, we showed that RAR␤2 transfection of Calu-1 cells enhanced the heterologous CTL response in both the induction and the effector phases by up to threefold. These results support the hypothesis that down-regulation of these genes (and possibly others) in RAR␤-deficient tumor cells contributes to immune system evasion, and suggest a novel therapeutic approach for this disease.-Toulouse, A., Loubeau, M., Morin, Pappas, J. J., Wu, J., Bradley W. E. C. RAR␤ involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis. FASEB
Retinoic acid (RA) is essential for development and epithelial differentiation, and has been shown in many epidemiological (1) and animal (2) studies to have tumor suppressive effects. These effects are mediated by two families of nuclear RA receptors (RARs), each comprising three genes (RAR␣, ␤, and ␥ as well as RXR ␣, ␤, and ␥; for review, see ref 3) . These receptors are transcription factors that specifically bind RA-responsive elements (RAREs) in the promoters of genes whose expression they control. Each gene codes for at least two functional isoforms (3); of these receptors, it is RAR␤, and more specifically the isoform ␤2, that has been implicated most frequently in suppression of epithelial cancers. For example, it has been shown that a majority of lung, breast, and other tumor-derived cell lines as well as the tumors themselves no longer express RAR␤ whereas expression is detected in the corresponding normal tissues (4 -10) . In addition, its forced reexpression in RAR␤ Ϫ lines reduces or eliminates various aspects of the tumor phenotype, including anchorage independence, focus formation and growth rate in vitro, and tumor formation in nude mice (reviewed in ref 11) . Transgenic mice expressing antisense or other constructs that down-regulate RAR␤2 develop lung and breast cancer (12, 13) . RAR␣ appears to mediate growth rate suppression in some breast tumor lines by modulating RAR␤ expression (14) , but otherwise there is little indication that the other RA receptors contribute to epithelial tumor suppression.
To understand the mechanism of RAR␤2-mediated tumor suppression, we have searched for genes regulated either directly or indirectly by RAR␤2 that could be implicated in this suppression. We considered it important to compare lines that were as similar as possible, so we made use of a panel of RAR-expressing derivatives of the Calu-1 cell line, in which RAR␤2 tumor suppression has been well characterized (15) . We then compared patterns of gene expression using the Atlas human cDNA array I and confirmed the differences for six of the cDNAs by an independent assay. In addition to RAR␤ itself, the expression levels of 27 cDNAs were reproducibly affected and 3 other genes were up-regulated by treatment with RA in a non-RAR␤-specific fashion. A striking characteristic of the results is the concerted nature of the effect the alterations are predicted to have on tumor behavior. Thus, for example, we found increased expression levels of several genes that regulate the immunogenicity of the tumor cell, most notably intercellular adhesion molecule 1 (ICAM-1), major histocompatibility complex (MHC) class I, and interleukin 1␤ (IL-1␤). Since the consequences of down-regulation of these would be the well-documented crippling of the immune system's capacity to detect and kill the nascent tumor, we hypothesized a role for RAR␤ in this function. To test this, we first confirmed that cell surface expression of the proteins was increased, and then demonstrated that the consequence of these changes was increased alloantigen-specific CTL response in both the induction and effector phases. These results have implications for understanding the nature of tumor evasion of immune surveillance.
MATERIALS AND METHODS

Cell culture
Two RAR␤-deficient epidermoid lung cancer cell lines, Calu-1 and SK-MES, and their transfected derivatives were maintained in alpha medium supplemented with 10% fetal bovine serum (Gibco BRL, Burlington, Canada) and 1% penicillinstreptomycin (Gibco BRL, Burlington, Canada) at 37°C in a humid atmosphere provided with 5% CO 2 . All transfectants were maintained in 400 g/ml of G418 (Gibco BRL). The Calu-1 derivatives C30 (RAR␤ Ϫ , transfected with the neomycin resistance gene only), C24, and C64 (both transfected with RAR␤2) have been described elsewhere (15) . The RAR␤1-transfected line (C␤10) was obtained by following exactly the same protocol, using the pSVL vector carrying the RAR␤1 cDNA sequences (A. Toulouse et al., unpublished results). The RAR␤2 ϩ derivative of SK-MES, named C102, was obtained by transfection with the RAR␤2 expression vector as described previously (15) . Where indicated, cells were treated with pharmacological doses (100 nM) of all-trans retinoic acid (Sigma, St. Louis, Mo.) prior to collection.
RNA preparation
All cells were cultured to 70% confluency, pelleted, and stored at Ϫ80°C for subsequent RNA extraction using the LiCl-urea method (16) . Poly Aϩ mRNA was prepared using Qiagen's Oligotex mRNA midi kit (Mississauga, Canada) and its quality was assessed following the manufacturer's instructions.
Atlas human cDNA expression array
The Atlas human cDNA array kit was purchased from Clontech Laboratories (Palo Alto, Calif.). All procedures for labeling and purifying the probes were accomplished by following manufacturer's recommendations. Complex ␣-32 PdCTP-labeled cDNA probes were generated by reverse transcription of mRNA from untreated Calu-1 cells as well as C30 (neo r ), C24 (RAR␤2 ϩ ), and C64 (RAR␤2 ϩ ) treated with RA for 48 h. The probes were purified by column chromatography (ChromaSpin) and met or exceeded the manufacturer's recommendation for specific activity. The membranes were hybridized in ExpressHyb solution overnight at 68°C, washed twice (20 min with 0.1ϫ SSC and 0.5% sodium dodecyl sulfate), and exposed for varying periods of time on Kodak XAR autoradiographic films.
RNA analysis
Northern blot analysis was performed according to standard protocols (17) . The blot was probed using the insert of an IL-1␤ construct generated by amplification of a cDNA fragment (primers: 5Ј-GCTGCTCTGGGATTCTCTTC-3Ј, 5Ј-AG-CACAGGACTCTCTGGGTA-3Ј), which was digested with HindIII and AccI prior to being cloned into pGEM-3Z. RNase protection assays were performed using Ambion's RPA II kit (Austin, Tex.) and the riboprobes were synthesized following standard protocols (17) . The actin probe used as control was described elsewhere (15) . The ID-3 probe was prepared by amplification of a cDNA fragment overlapping nucleotides 342 to 751 (primers: 5Ј-GCACCTCTGGACTCACTC-3Ј, 5Ј-TGGAGGTGTCAGGACACG-3Ј). The polymerase chain reaction (PCR) product was digested with SmaI; a 409 bp fragment was isolated and cloned into the SmaI site of pGEM-3Z (Promega, Madison, Wis.). The plasmid was linearized using HindIII and the probe was synthesized using T7 RNA polymerase. The GADD-45 probe was obtained from Dr. P. A. Dion.
Immunological reagents
Lympholite H and phycoerythrin-conjugated goat anti-mouse IgG1 were purchased from Cedarlane (Hornby, Ontario, Canada). FITC-conjugated mAb (clone W6/32) against the conserved region of the human HLA class I antigen was obtained from Sigma (Oakville, Ontario, Canada), and mAb against ICAM-1 (clone 8.4A6) was from BioSource International (Camarillo, Calif.). Chromium-51 was purchased from ICN (Costa Mesa, Calif.).
Flow cytometry
One-color flow cytometry analysis was performed as follows. Where indicated, the cells were treated with RA at 100 nM for 5 or 7 days. To detect MHC class I proteins, 10 6 cells were incubated with 2 g of FITC-conjugated monoclonal antibody W6/32 against human MHC class I antigen for 30 min on ice. The cells were then washed with phosphate-buffered saline (PBS) and fixed in 1% paraformaldehyde in PBS. To detect ICAM-1 protein expression, 10 6 cells were incubated with 1 g of monoclonal antibody 8.4A6 for 30 min on ice and washed with PBS. These cells were then incubated with 600 ng of a goat anti-mouse IgG-1 antibody conjugated to R-phycoerythrin. The samples were read on a Profile I flow cytometer (Coulter, Burlington, Ontario, Canada). Two-color cytometry was performed in the same way except that labeling with the two antibodies conjugated with the respective fluorochromes was done simultaneously. All cytometric determinations were performed at least twice.
Cytotoxic lymphocytes (CTL) assay
Peripheral blood mononuclear cells (PBMC) were prepared as described previously (18) . The Calu-1 derivatives C30 and C64 were cultured in either the presence or absence of RA (100 nM) for 5 days, then treated with mitomycin C. These mitomycin C-treated cells were used as stimulator cells for PBMC in a 5 day alloreactive culture in the absence of exogenous RA (18) . The culture was performed in 24-well plates with 2 ϫ 10 6 PBMC/ml and 2 ϫ 10 6 stimulators/ml in a final volume of 2 ml/well. IL-2 (10 U/ml) was added at the beginning of the culture. After 5 days, the cells were washed and recounted. Fresh C30 and C64 cells that had been treated with 100 nM RA for 5 days prior to the assay were labeled with 51 Cr and used as targets in a standard 4 h 51 Cr release assay as described in a previous publication (19) . The ratios of effector/target cells were set at 30:1, 10:1, 3:1, and 1:1. A fixed number of 15,000 target cells/well was used for all the determinations. Samples were in triplicate. The percentage of lysis was calculated as % ϭ (cpm of test sample Ϫ cpm of spontaneous release) (cpm of maximal release Ϫ cpm of spontaneous release)
RESULTS
To screen for differential expression of hundreds of genes, we used Clontech's Atlas human cDNA expression array I, which allows for direct screening of 588 cDNAs each spotted in duplicate and arranged in sextants, A to F (see Fig. 1 ). Nine additional genes that are thought to be constitutively expressed are displayed on the bottom row, G. Three negative controls include lambda, M13, and plasmid DNA, also in row G, and genomic DNA is arrayed along the right-hand and bottom borders to allow assessment of uniformity of hybridization. The cDNAs present on the membrane have been shown to be expressed in a regulated fashion and are involved in key cellular processes. Hybridizations were performed on four separate membranes, with probes generated from Calu-1 (a RAR␤-deficient cell line) cells grown in the absence of added RA and three transfected derivatives grown in the presence of 100 nM RA for 48 h: C24, C64 (both RAR␤2-expressing), and C30 (a neo r -derivative), which we hereafter call C24-RA, C64-RA, and C30-RA. The latter was chosen as the RAR␤-deficient line to be grown in the presence of RA because we have established that the parental Calu-1 line occasionally expresses trace levels of RAR␤ when grown in RA-supplemented medium, whereas C30 does not (data not shown). Previous work (11) had shown that the RNA fingerprints of these four lines, as well as two other lines derived from Calu-1 by transfection of RAR␤1, varied from one line to another in less than 0.5% of their transcripts as determined by arbitrarily primed reverse transcription PCR (20) , so the probes were comparable.
Uniformity of hybridization was demonstrable by equality of intensity of hybridization of the genomic DNA spots on the extreme right border and the bottom row of section G on the original films. The negative controls built into the membrane in row G were all completely negative on all membranes (Fig.  1 ). To accommodate differences in specific activities of the probes used, the membranes were exposed for varying lengths of time so that meaningful comparisons could be made among all the membranes. A total of 71% of the cDNAs (428/597) were detectable after a 4 day exposure of the C64-RA-hybridized membrane (results available on request from W. E. C. Bradley), with somewhat lower numbers for the other membranes due to lower specific activity of the probes. To evaluate the array results, spot densitometries were performed using the NIH Image software on the membranes probed with Calu-1, C30-RA, and C64-RA. Since the probe derived from C24-RA was weaker, densitometry of the corresponding array was less informative, and this array was used primarily to confirm by visual inspection results from the other arrays. Densitometric values for each spot were normalized to the mean value of the genomic DNA control spots on the membrane. Relative ratios were then calculated between the membranes (C64-RA/ Calu-1 and C64-RA/C30-RA). Spots that were consistently changed in both ratios are reported in Table 1 . Some of the changes are of the order of 1.5 to 2.5; these may be of marginal physiological significance, but are included for completeness (see Discussion).
A measure of the confidence one can place in these results is the comparison of their consistency between the two comparisons of RAR␤ ϩ vs. RAR␤-derived probes. A total of 28 cDNAs (including RAR␤) were found to be altered in a consistent manner, with 21 being specifically up-regulated and 7 down-regulated in the presence of RAR␤2 (Table 1). Only three cDNAs varied in intensity in a way, suggesting regulation by RA rather than specifically by RAR␤2 (most probably by other RARs present in the cells), namely, TNF receptor 1 (spot C1m), FAS ligand (spot C4m), and ID-2 (spot D1g) ( Table 1 ). The ratios for these were close to 1.0 in C64-RA/ C30-RA while being two-to threefold higher in the C64-RA/Calu-1 comparison, which suggests up-regulation in the RA-treated cells. A limited number of spots varied in what we interpret to be a clonal fashion, the intensities varying on the three membranes but not in a way suggestive of RA or RAR␤2 regulation (Table 1 ). In addition, the results for 15 of the spots (in general, the more intense ones; identified in Table 1 ) were confirmed using the fourth membrane probed with RA-treated C24 cDNA. In no case was a discordance seen between this set of results and the others. As expected, the expressed housekeeping controls in row G are also of similar relative intensity from one cell line to the other, with the striking exception of MHC class I (G14, see below), which is up-regulated by at least threefold in the RAR␤2-positive line (confirmed with the C24-RA-probed array). To further assess the dependability of the array results, some genes listed in Table 1 have been tested by RNase protection or Northern blot for relative expression levels in a panel of RAR␤1-positive (C␤10), RAR␤2-positive (C24 and C64), and RAR␤-deficient (C30) derivatives of Calu-1 cells. RAR␤ itself was detected in the C64-RA and C24-RA probed arrays (albeit at a low intensity) but was not visible in the two arrays probed with cDNA from the RAR␤-deficient cells (Table 1) , and this is concordant with RNase protection and PCR assays (ref 15 and data not shown). Probes were also generated for several other genes that gave differences on both sets of arrays (GADD-45, ID-3, ICAM-1, and IL1-␤, corresponding to C7f, D1d, E5h, and F5m, respectively). The results of RNase protection and Northern analyses of message levels of these genes ( Table 2 and results not shown) confirmed their differential expression. Only slight increases in the levels of expression were seen upon RA treatment of RAR␤2-deficient cell lines (Calu-1, C30, and C␤10). However, in the case of IL-1␤ and ID-3, transfection by RAR␤2 resulted in a substantial RA response of about threefold or more. For GADD-45, an increase was seen in both RAR␤2-transfected lines in comparison to Calu-1 and C30 in absence of retinoic acid, but no further increase was seen upon addition of exogenous RA. It may be that the physiological levels of RA present in the cells were sufficient to mediate the activation of this gene, but we cannot confirm this yet.
The modulation of the MHC class I and ICAM-1 genes may be of importance if we regard it in light of the theory of immune surveillance. The products of these genes are involved in the presentation of foreign or tumor antigens to cytotoxic cell precursors and in enhancing T cell and antigen-presenting cell interaction (21, 22) . If down-regulation of these molecules occurs in tumor cells, they will have a better chance of evading the immune system since the signaling strength of any tumor-specific antigen at the cell surface would necessarily be compromised.
Since ICAM-1 and MHC class I can play these central roles in eliciting an immune response only if they are displayed on the cell surface, it was important to determine whether the RAR␤2-induced increases in mRNAs were reflected at this level. We therefore assayed surface ICAM-1 and MHC class I by flow cytometry in two lung tumor lines and their RAR␤ ϩ transfectants. C30 (neo r -transfectant, RAR␤ Ϫ ) and C64 (RAR␤2 ϩ ) cells were labeled as described in Materials and Methods and analyzed by flow cytometry. The results in Table 3 show that the mean fluorescence intensity (MFI) of ICAM-1 protein is ϳthreefold higher on the cell surface of the RAR␤2-transfected C64 cells than on the C30 cells. Treating the cells with 100 nM RA for 7 days increased the expression in both cell lines but the increase was greater in C64 cells than in C30 cells, as demonstrated in Table 3 (2.7-fold vs. 1.7-fold). Table  3 also shows results obtained with antibody W6/32 against MHC class I proteins. As seen for ICAM-1 protein, the RAR␤2-transfected C64 cells show slightly higher MHC class I MFI than C30 cells prior a Assays of IL-1␤ (RPA and Northern blot), ID-3 (RPA), and GADD-45 (Northern blot) were scanned using an Alpha Imager (Alpha Innotech Corp.). Ratios of band intensity to the band intensity of the internal control (actin) were calculated and these values were normalized to Calu-1 (without RA) ϭ 1.0. Measurements were made using film exposure times to give band intensities in the linear range.
b These values are underestimates because the amount of material loaded was low.
to RA treatment. The 7 day incubation in the presence of retinoic acid resulted in the induction of MHC class I molecules in C64 cells, but no augmentation was seen with C30 cells after the treatment (Table 3) .
To determine whether the RAR␤-induced increase in expression of these proteins could be generalized to other lines, SK-MES, which is stably RAR␤ deficient (5), was transfected as described (15) and a derivative, C102, was characterized and shown to express RAR␤2 (results not shown). SK-MES and C102 were grown in the presence or absence of RA (as above for Calu-1 derivatives) for 5 days and the proteins were assayed simultaneously by flow cytometry (Table 3) . Again, an increase of ϳtwofold in ICAM-1 was seen in untreated C102 and the increase in MHC class I was more than threefold compared to that in SK-MES cells. RA treatment increased levels of both proteins to a similar extent (ϳ30%) in both the parental and the transfected cell lines. This increase is less pronounced than seen in the Calu-1 RAR␤2ϩ cells but, as mentioned above for GADD-45, it is possible that the basal level of bioavailable RA is sufficient in SK-MES to stimulate expression of these genes. In any event, the transfection of RAR␤2 had a similar effect on cell surface expression of the two proteins in both cell lines. Furthermore, a similar effect has been observed on transfection of RAR␤2 into breast and colon cancer cell lines (J. Pappas and W. E. C. Bradley, unpublished results), which supports the observations reported here and suggests that this RAR␤2 effect applies to other cancers in addition to lung.
To show that this increase in potentially immunogenic proteins on the surface of the RAR␤2 ϩ cells actually had a physiological effect, we performed a CTL assay on these cells (23) . We first isolated PBMC from heterologous donors and incubated them with either C30 or C64 stimulator cells that had been treated with RA for 5 days prior to incubation with the PBMC (see Materials and Methods). The PBMC were then incubated with 51 Cr-labeled target cells (RA-pretreated C64 cells or, for some combinations, RA-pretreated C30 cells) and the extent of lysis of these targets was determined. The C64 (RAR␤2-expressing) line was 2.5-to 3-fold more efficient than the control line (C30) in inducing CTL effector cells (one experiment shown in Fig. 2 ) against a C64 target, as judged by chromium release. In addition, when used as target cells, the RAR␤2 ϩ line was 1.3-to 2-fold more susceptible to lysis by C64 RA-stimulated CTL cells than was the C30 RAR␤ Ϫ line (Fig. 3) .
DISCUSSION
In this paper we report the finding of genes that are regulated either directly or indirectly by RAR␤. Most of the changes were in the direction of up-regulation, and this was particularly true for those genes where the change was substantial; for example, among the cDNAs listed in Table 1 , 14 had intensities that differed by at least 2.5-fold in one of the comparisons; of these, however, only one, VRP, was down-regulated in the RAR␤-expressing lines. We also found that three of the genes on the array were up-regulated by RA without specific dependence on the RAR␤ receptor, most probably through the other RA receptors expressed in these cells. We also tested six of the genes by an independent assay for RNA or protein level (Tables 2 and 3 and data not shown) and found up-regulation to levels similar to those shown by the array experiments. Based on this high degree of concordance, we are confident that the array results reflect genuine regulatory effects of RAR␤2, at least in Calu-1 cells. The subsequent demonstration of up-regulation at the protein level of two of the genes in another cell line, SK-MES, increases our confidence that our results can be generalized.
Consistent with the high level of reliability of the array, several of the genes listed in Table 1 have previously been reported to be regulated by RA or other retinoids-for example, GADD-45 (24), ICAM-1 (25), IL-1␤ (26)-and the results presented here allow us to propose RAR␤ as the specific receptor mediating this regulation. Some other genes have been found by others to be controlled specifically by RAR␤ (MHC class I and recently IGF-BP3) and our data confirm the involvement of RAR␤2 as a regulator of these genes (27, 28) .
Of particular interest in the work presented here is the identification of genes that may be the downstream effectors of the RAR␤2-mediated tumor suppression. Table 1 shows the functions of the regulated genes, and it is noteworthy that many of them are consistent with this role for RAR␤2. These results highlight several potentially synergistic pathways regulated by RAR␤2 that are involved in the control of cell behavior. In addition to the two major group discussed below, the expression of genes involved in repair (GADD-45), IGF signaling (IGF-BP3), as well as certain cell cycle regulators (p14) would be expected to contribute in a concerted fashion to suppress the development of tumor cells (29) . The genes identified in this study as well as others yet to be identified will therefore provide a better understanding of the mechanisms by which RAR␤2 promotes tumor suppression.
Of particular interest is that about a third (9/31) of the genes influence decision-making in the commitment to apoptosis, and another one-quarter are involved in provocation of an immune response. It is possible that the observed clustering of regulated genes into two groups reflects the selection of genes presented on the array; however, in light of the tumor suppressive properties of RAR␤2 and the modification of the CTL response (discussed below), we believe they represent some of the mechanisms involved in RAR␤2-mediated tumor suppression.
For the first of these major groups, genes that both promote and inhibit apoptosis are up-regulated, but close inspection of the arrays indicates that most of the latter are expressed at a very low level, so the predominant effect of RAR␤2 may be to enhance the probability that the cell will commit to apoptosis if other requirements are fulfilled. Of particular interest within this group is the ID family of inhibitors of differentiation and DNA binding proteins. All three members on the array are up-regulated by RA, and in two of the cases-ID-1 and ID-3-specifically by RAR␤2. In addition, the latter two are expressed at substantial levels. These genes promote passage from G1 to S-phase and have been shown to be potent inducers of apoptosis (30) . Their functions and expression patterns overlap (31), suggestive of functional redundancy, so the conclusion that RAR␤2 up-regulates them, if confirmed on analysis of other lines, may point to an important mechanism of defense against tumorigenesis.
The second group of genes that have similar function is that involved in immune response. As documented above, two genes essential for eliciting an effective cytotoxic immune response, MHC class I (G14) and ICAM-1 (E5h), are up-regulated by RAR␤2. The results presented in Table 3 and those from Pappas and Bradley (unpublished results) also confirm that the effect of RAR␤ on levels of the two surface proteins is not restricted to one cell line. In addition, increased levels of several inflammatory cytokines that enhance this response (IL-1␤, MIP2␣, and IL-8) were seen. These are potent attractants and activators of macrophages, granulocytes, and mast cells, and consequently of the immune system's ability to eliminate any lesions (reviewed in ref 32) . In this context a reduced level of expression of RAR␤ would be hypothesized to weaken the overall immune response by compromising several of its components.
When this was tested in a heterologous CTL assay, the results (Figs. 2 and 3) showed that, at least as measured by this assay, the immune response would indeed be weakened against RAR␤-deficient tumor cells. RAR␤2-transfected cells were better stimulators and targets of the CTLs, establishing a role for RAR␤2 in maintaining an effective immune response. The potential implications of these results are of major importance as they establish a physiological role for some of the genes whose expression is influenced by RAR␤2. This physiological role may be exploitable for therapeutic benefits if RAR␤2 expression can be up-regulated by gene therapy or by simple administration of retinoids, as has been shown in patients at risk (33, 34) .
